Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1274637 | 1.00 | CALCRL (0.34) | CALCRLRIPK1HRH3OPRL1HDAC3 | |
| SCHEMBL1274728 | 0.89 | CALCRL (0.41) | CALCRLRIPK1FFAR4HSD11B1PTGDR2 | |
| SCHEMBL1274559 | 0.81 | CALCRL (0.41) | CALCRLRIPK1FFAR4PTGDR2 | |
| SCHEMBL978376 | 0.79 | RIPK1 (0.36) | CALCRLRIPK1FFAR4PTGDR2 | |
| SCHEMBL15354521 | 0.78 | HRH3 (0.36) | RIPK1HRH3OPRL1HTR4 | |
| SCHEMBL12263103 | 0.76 | HRH3 (0.35) | RIPK1HRH3HTR4 | |
| SCHEMBL1274873 | 0.75 | SMN1; SMN2 (0.46) | HDAC1HDAC6PTGDR2 | |
| SCHEMBL17022981 | 0.73 | CALCRL (0.42) | CALCRLRIPK1 | |
| SCHEMBL1274826 | 0.72 | RIPK1 (0.37) | CALCRLRIPK1FFAR4PTGDR2 | |
| SCHEMBL13599430 | 0.72 | CALCRL (0.59) | CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029575-B1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20110245240-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2011-10-06 | — | — | US | disclosed |
| EP-2341919-A1 | CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010042356-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245240-A1 | CGRP RECEPTOR ANTAGONISTS | CCKAR, CALCRL, QRFPR | CALCRL 2/4885RIPK1 4037/4885HRH3 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.